Israel to offer Pfizer booster shot against 19 to the over-60s



* Israel was a world leader in vaccine rollout

* Infections have spiked due to Delta variant

* Booster campaign to start on Sunday, reports say

By Jeffrey Heller

JERUSALEM, July 29 (Reuters) - Israel will begin offering a third shot of the Pfizer PFE.N /BioNTech 22UAY.DE COVID-19 vaccine to people aged over 60, a world first in efforts to slow the spread of the highly contagious Delta variant, a healthcare provider and Israeli media said on Thursday.

Those eligible will be able to get the booster shot starting on Sunday as long as they received their second dose more than five months ago, Maccabi Healthcare Services said in a statement that confirmed reports on Channel 13 TV and Kan public radio.

Israel was a world leader in the vaccination rollout, with many seniors getting their shots in December, January and February as they were regarded as the most vulnerable sector of the population.

But since the emergence of the Delta variant, the health ministry has twice reported a drop in the vaccine's efficacy against infection and a slight decrease in its protection against severe disease.

The booster campaign, due to be launched by Prime Minister Naftali Bennett at a news conference later in the day, will effectively turn Israel into a testing ground for a third dose before approval by the U.S. Food and Drug Administration (FDA).

Pfizer said on Wednesday it believes people need the additional dose to keep protection against the coronavirus high. The company says it could apply for U.S. emergency authorization for booster shots as early as August.

A panel of Israeli vaccination experts advising the health ministry gave approval for the campaign late on Wednesday.

Maccabi, one of Israel's largest healthcare providers, said in its statement that eligible patients were welcome to schedule their vaccination appointment via the Internet or its call centre.

Last week, the health ministry estimated the Pfizer vaccine was only 41% effective at halting symptomatic infections over the past month. Protection against severe disease remained strong at 91%.

Some experts have criticised the ministry's analysis because of possible bias that could be skewing the data. Others said Israel should wait a little longer to receive more information about the safety and effectiveness of a third shot.

Around 57% of Israel's 9.3 million population has been vaccinated. Around 160 people are hospitalised with severe symptoms and daily new infections have spiked to more than 2,000, up from a handful of cases per day a few months ago.

The cabinet is hoping that the vaccines will allow it to avoid costly lockdowns by protecting those most vulnerable from severe illness.


Additional reporting by Dan Williams and Rami Ayyub; Editing by Mike Harrison and Mark Heinrich

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Gumagamit kami ng cookies para mabigyan ka ng mahusay na karanasan sa aming website. Magbasa pa o palitan ang iyong cookie settings.

Babala sa Risk: Ang iyong kapital ay maaaring malugi. Ang mga produktong naka-leverage ay maaaring hindi para sa lahat. Tingnan ang aming Risk Disclosure.